A Phase 1 Trial of PT2977, a HIF-2α Inhibitor, in Patients With clear cell renal cell carcinoma (ccRCC).

Next Previous
Trial Profile

A Phase 1 Trial of PT2977, a HIF-2α Inhibitor, in Patients With clear cell renal cell carcinoma (ccRCC).

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2017

At a glance

  • Drugs PT 2977 (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions

    • Most Recent Events

    • 27 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top